BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $562,122 | -16.6% | 8,258 | 0.0% | 0.05% | -10.9% |
| Q2 2023 | $674,101 | +7.1% | 8,258 | -2.6% | 0.06% | -5.2% |
| Q1 2023 | $629,205 | -14.5% | 8,481 | -4.5% | 0.06% | -9.4% |
| Q4 2022 | $735,643 | +14.2% | 8,876 | +291.2% | 0.06% | 0.0% |
| Q3 2022 | $644,000 | -20.6% | 2,269 | -3.0% | 0.06% | -21.0% |
| Q2 2022 | $811,000 | -20.4% | 2,340 | -0.6% | 0.08% | -9.0% |
| Q1 2022 | $1,019,000 | -31.4% | 2,354 | -18.0% | 0.09% | -19.1% |
| Q4 2021 | $1,485,000 | -8.2% | 2,871 | -14.0% | 0.11% | -17.3% |
| Q3 2021 | $1,617,000 | +1.8% | 3,337 | -5.4% | 0.13% | +1.5% |
| Q2 2021 | $1,588,000 | +17.8% | 3,527 | -0.1% | 0.13% | +5.6% |
| Q1 2021 | $1,348,000 | -3.6% | 3,529 | -19.8% | 0.12% | +2.5% |
| Q4 2020 | $1,398,000 | +36.9% | 4,402 | +6.8% | 0.12% | +9.0% |
| Q3 2020 | $1,021,000 | -6.2% | 4,122 | 0.0% | 0.11% | -13.3% |
| Q2 2020 | $1,088,000 | +61.2% | 4,122 | +15.9% | 0.13% | +43.8% |
| Q1 2020 | $675,000 | -13.8% | 3,558 | -0.2% | 0.09% | +20.3% |
| Q4 2019 | $783,000 | +8.3% | 3,565 | -3.5% | 0.07% | -1.3% |
| Q3 2019 | $723,000 | -0.4% | 3,696 | +6.1% | 0.08% | -23.5% |
| Q2 2019 | $726,000 | -47.2% | 3,482 | -49.8% | 0.10% | +1.0% |
| Q1 2019 | $1,376,000 | +87.0% | 6,934 | +36.3% | 0.10% | +79.6% |
| Q4 2018 | $736,000 | – | 5,088 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |